Website
N/ATelephone
61.3.9824.5254
Address
Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053
Description
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.07 - 0.1
Trade Value (12mth)
AU$2,501.00
1 week
9.21%
1 month
13.7%
YTD
-3.49%
1 year
3.75%
All time high
15.598
EPS 3 yr Growth
0.000%
EBITDA Margin
-329.80%
Operating Cashflow
-$2m
Free Cash Flow Return
-11.50%
ROIC
-17.60%
Interest Coverage
-616.60
Quick Ratio
8.80
Shares on Issue (Fully Dilluted)
228m
HALO Sector
Healthcare
Next Company Report Date
30-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 May 16 |
Immuron Company Presentation - May 2016
×
Immuron Company Presentation - May 2016 |
31 May 12 |
Chairman`s Address and Presentation to EGM (31 May)
×
Chairman`s Address and Presentation to EGM (31 May) |
31 August 22 |
Appendix 4E and Preliminary Final Report
×
Appendix 4E and Preliminary Final Report |
31 August 22 |
FY22 Results and Business Update Presentation
×
FY22 Results and Business Update Presentation |
30 September 21 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 09 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 October 23 |
Immuron CEO, Steven Lydeamore to present at AusBioInvest
×
Immuron CEO, Steven Lydeamore to present at AusBioInvest |
30 October 13 |
2013 Notice of Annual General Meeting
×
2013 Notice of Annual General Meeting |
30 October 08 |
Presenting at Rodman and Rensaw 5th Annual Global Conference
×
Presenting at Rodman and Rensaw 5th Annual Global Conference |
30 November 11 |
AGM Chairman`s address, presentations and results of meeting
×
AGM Chairman`s address, presentations and results of meeting |
30 May 23 |
Immuron Initiates Recruitment of Travelan Clinical Study
×
Immuron Initiates Recruitment of Travelan Clinical Study |
30 June 23 |
Immuron Chairman Transition
×
Immuron Chairman Transition |
30 December 22 |
Change in substantial holding
×
Change in substantial holding |
30 August 23 |
Appendix 4E Preliminary Final Report
×
Appendix 4E Preliminary Final Report |
30 August 19 |
Appendix 4E & Annual Report to shareholders
×
Appendix 4E & Annual Report to shareholders |
30 August 16 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
29 September 11 |
Annual Report for Year Ended 30 June 2011
×
Annual Report for Year Ended 30 June 2011 |
29 September 06 |
20006 Annual Report
×
20006 Annual Report |
29 October 20 |
2020 AGM Presentation
×
2020 AGM Presentation |
29 November 16 |
2016 AGM Presentation
×
2016 AGM Presentation |
29 November 16 |
Results of 2016 Annual General Meeting
×
Results of 2016 Annual General Meeting |
29 November 13 |
2013 Annual General Meeting CEO Presentation
×
2013 Annual General Meeting CEO Presentation |
29 November 13 |
Results of 2013 Annual General Meeting
×
Results of 2013 Annual General Meeting |
29 November 10 |
AGM Presentations
×
AGM Presentations |
29 November 10 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
29 August 22 |
Immuron CEO, Steven Lydeamore, to host an investor webinar
×
Immuron CEO, Steven Lydeamore, to host an investor webinar |
29 April 19 |
Immuron CEO to Present at the ThinkEquity Conference
×
Immuron CEO to Present at the ThinkEquity Conference |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.